natgillin/translations-raw huggingface dataset:
Following a single 400 mg oral dose of [14C]-sofosbuvir, mean total recovery of the dose was greater than 92%, consisting of approximately 80%, 14%, and 2.5% recovered in urine, faeces, and expired air, respectively.
Nakon jedne peroralne doze od 400 mg [14C]-sofosbuvira, srednja vrijednost ukupno otkrivene doze bila je veća od 92% i sastojala se od približno 80% one otkrivene u mokraći, 14% u stolici i 2,5% u izdahnutom zraku.
Following a single 420 mg Repatha intravenous dose, the mean (SD) steady-state volume of distribution was estimated to be 3.3 (0.5) L, suggesting evolocumab has limited tissue distribution.
Nakon primjene jednokratne intravenske doze lijeka Repatha od 420 mg, srednja vrijednost (SD) volumena distribucije u stanju dinamičke ravnoteže procjenjuje se na 3,3 (0,5) L, ukazujući na ograničenu distribuciju evolokumaba u tkivima.
Following a single 50 mg dose of 14C-saxagliptin, 24 %, 36 %, and 75 % of the dose was excreted in the urine as saxagliptin, its active metabolite, and total radioactivity, respectively.
Nakon jednokratne doze 14C-saksagliptina od 50 mg, 24% doze izlučilo se mokraćom u obliku saksagliptina, 36% u obliku njegova aktivnog metabolita, a 75% kao ukupna radioaktivnost.
Following a single 50 mg dose of 14C-saxagliptin, 24%, 36%, and 75% of the dose was excreted in the urine as saxagliptin, its major metabolite, and total radioactivity respectively.
Nakon jednokratne doze od 50 mg 14C-saksagliptina, 24% se izlučilo mokraćom u obliku saksagliptina, 36% u obliku njegova glavnog metabolita, a 75% kao ukupna radioaktivnosti.
Following a single 50 mg dose of 14C-saxagliptin, 24%, 36%, and 75% of the dose was excreted in the urine as saxagliptin, its major metabolite, and total radioactivity respectively.
Nakon primjene jedne doze od 50 mg 14C-saksagliptina 24% doze izlučilo se mokraćom u obliku saksagliptina, 36% u obliku njegova glavnog metabolita, a 75% u obliku ukupne radioaktivnosti.
Following a single 800 mg oral dose of 14C-boceprevir, approximately 79% and 9% of the dose was excreted in faeces and urine, respectively, with approximately 8% and 3% of the dosed radiocarbon eliminated as boceprevir in faeces and urine.
Nakon jednokratne peroralne doze od 800 mg 14C-boceprevira, oko 79% doze izluči se stolicom, a oko 9% mokraćom, dok se oko 8% primijenjenog radiougljika eliminira kao boceprevir stolicom, a oko 3% mokraćom.
Following a single 90 mg oral dose of [14C]-ledipasvir, mean total recovery of the [14C]-radioactivity in faeces and urine was 87%, with most of the radioactive dose recovered from faeces (86%).
Nakon jedne peroralne doze od 90 mg [14C]-ledipasvira, srednja vrijednost ukupno otkrivene [14C]-radioaaktivnosti u stolici i mokraći iznosila je 87 %, s time da je najviše radioaktivne doze otkriveno u stolici (86 %).
Following a single administration, the veterinary medicinal product will prevent flea infestation for one month and further flea multiplication by inhibiting flea emergence in the environment of the cat for 3 months.
Nakon jednokratne primjene, veterinarsko-medicinski proizvod sprječava infestaciju buhama tijekom mjesec dana i daljnje razmnožavanje buha inhibicijom razvoja buha u mačjoj okolini tijekom 3 mjeseca.
Following a single administration, the veterinary medicinal product will prevent flea infestation for one month and prevent further flea multiplication by inhibiting flea emergence in the environment of the cat for 3 months.
Nakon jednokratne primjene, veterinarsko-medicinski proizvod sprječava infestaciju buhama tijekom mjesec dana i daljnje razmnožavanje buha inhibicijom razvoja buha u mačjoj okolini tijekom 3 mjeseca.
Following a single administration, the veterinary medicinal product will prevent further flea infestation for at least 4 weeks.
Nakon jedne primjene veterinarsko medicinski proizvod će spriječiti daljnju infestaciju buhama kroz najmanje 4 tjedna.
Following a single administration, the veterinary medicinal product will prevent infestation for one month.
Nakon jednokratne primjene, veterinarsko-medicinski proizvod sprječava infestaciju tijekom mjesec dana.
Following a single administration, the veterinary medicine will prevent infestation for one month.
Nakon pojedinačnog tretmana, veterinarsko-medicinski proizvod će spriječiti infestaciju tijekom mjesec dana.
Following a single application onto the skin, the 2 active substances spread over the body surface of the cat within the first day after application.
Nakon pojedinačne primjene na kožu, dvije djelatne tvari šire se preko površine tijela mačke unutar prvog dana nakon primjene.
Following a single application onto the skin, the three active substances spread over the body surface of the dog within the first day after application.
Nakon pojedinačne primjene na kožu, tri djelatne tvari šire se preko površine tijela psa unutar prvog dana nakon primjene.
Following a single dose of 10 mg/kg, the elotuzumab clearance was 13.2 mL/day/kg.
Nakon jednokratne doze od 10 mg/kg, klirens elotuzumaba iznosio je 13,2 ml/dan/kg.
Following a single dose of 40 mg esomeprazole the mean are under the plasma concentration-time curve is approximately 30% higher in females than in males.
Nakon jednokratne doze od 40 mg esomeprazola srednja vrijednost površine ispod krivulje je približno 30% veća u žena nego u muškaraca.
Following a single dose of 500 mg bosutinib with food, bosutinib had a mean apparent volume of distribution of 9,560 ± 3,030 L, suggesting that bosutinib is extensively distributed to extra-vascular tissue.
Nakon jedne doze od 500 mg bosutiniba s hranom, bosutinib je imao aritmetičku sredinu prividnog volumena distribucije od 9,560 ± 3,030 l, što upućuje da se bosutinib opsežno distribuira u ekstravaskularno tkivo.
Following a single dose of 600 mg of abacavir, the mean (CV) Cmax is 4.26 µg/ml (28%) and the mean (CV) AUC is 11.95 µg.h/ml (21%).
Nakon jednokratne doze abakavira od 600 mg, srednja vrijednost (CV) Cmax iznosi 4,26 µg/ml (28%), a srednja vrijednost (CV) AUC 11,95 µg.h/ml (21%).
Following a single dose of Numient in patients with Parkinson’s disease the plasma AUC and Cmax of levodopa was higher in females than males (on average, 37% for AUC and 35% for Cmax).
Nakon pojedinačne doze Numienta u bolesnika oboljelih od Parkinsonove bolesti, AUC i Cmax vrijednosti levodope u plazmi bile su više u žena nego u muškaraca (u prosjeku, 37 % za AUC i 35 % za Cmax).
Following a single intravenous 150-mg dose of fosaprepitant administered as a 20-minute infusion to healthy volunteers, the mean AUC0-∞ of aprepitant was 35.0 µghr/ml and the mean maximal aprepitant concentration was 4.01 µg/ml.
Nakon jednokratne 20-minutne infuzije fosaprepitanta u dozi od 150 mg u zdravih dobrovoljaca, srednji AUC0-∞ aprepitanta iznosio 35,0 μgh/ml, a njegova srednja vršna koncentracija 4,01 μg/ml.
Following a single intravenous administration of 500 mg avibactam as a 30-minute IV infusion, the elderly had a slower terminal half-life of avibactam, which may be attributed to age related decrease in renal clearance.
Nakon jednokratne intravenske primjene avibaktama u dozi od 500 mg u obliku 30-minutne i.v. infuzije, kod starijih je osoba terminalni poluvijek avibaktama bio dulji, što se može pripisati dobno uvjetovanom smanjenju bubrežnog klirensa.
Following a single intravenous administration to patients with asthma, the mean systemic clearance (CL) ranged from 1.9 to 3.3 mL/day/kg, with a mean terminal half-life of approximately 20 days.
Nakon intravenske primjene jedne doze u bolesnika s astmom, srednja vrijednost sistemskog klirensa (CL) kretala se u rasponu od 1,9 do 3,3 ml/kg na dan, a srednji terminalni poluvijek iznosio je približno 20 dana.
Following a single intravenous dose of 1000 mg in healthy volunteers AUC in skin blister fluid amounted (bound and unbound dalbavancin) to approximately 60 % of the plasma AUC at day 7 post-dose.
Nakon jednokratne intravenske doze od 1000 mg u zdravih dobrovoljaca AUC u tekućini u mjehurićima na koži (vezani i nevezani dalbavancin) iznosio je oko 60 % AUC-a plazme 7. dan nakon primjene doze.
Following a single intravenous dose of 12.5 mg alogliptin to healthy subjects, the volume of distribution during the terminal phase was 417 L indicating that the drug is well distributed into tissues.
Nakon primjene jednokratne intravenske doze od 12,5 mg alogliptina u zdravih ispitanika, volumen distribucije tijekom terminalne faze bio je 417 l što pokazuje da se lijek dobro distribuira u tkiva.
Following a single intravenous dose of 12.5 mg alogliptin to healthy subjects, the volume of distribution during the terminal phase was 417 L indicating that the drug is well distributed into tissues.
Nakon primjene jednokratne intravenske doze od 12,5 mg alogliptina zdravim ispitanicima, volumen distribucije tijekom terminalne faze bio je 417 l što pokazuje da se lijek dobro distribuira u tkiva.
Following a single intravenous dose of [14C]alendronate, approximately 50 % of the radioactivity was excreted in the urine within 72 hours and little or no radioactivity was recovered in the faeces.
Nakon primjene jedne intravenske doze [14C]-alendronata, približno 50% radioaktivnosti eliminira se mokraćom tijekom 72 sata, dok je u fecesu ustanovljeno malo ili ništa radioaktivnosti.
Following a single IV administration, the mean volume of distribution was 115  19 mL/kg.
Nakon jednokratne intravenske primjene srednji volumen distribucije iznosio je 115 ± 19 ml/kg.
Following a single oral (10 mg/kg) administration of [14C] radiolabelled bosutinib to lactating Sprague-Dawley rats, radioactivity was readily excreted into breast milk as early as 0.5 hr after dosing.
Nakon jedne oralne (10 mg/kg) primjene radioaktivno [14C] obilježenog bosutiniba u Sprague-Dawley štakora tijekom laktacije, radioaktivnost se odmah izlučila u majčino mlijeko nakon samo pola sata od doze.
Following a single oral administration of [14C]-pomalidomide (2 mg) to healthy subjects, approximately 73% and 15% of the radioactive dose was eliminated in urine and faeces, respectively, with approximately 2% and 8% of the dosed radiocarbon eliminated as pomalidomide in urine and faeces.
Nakon jednokratne peroralne primjene [14C]-pomalidomida (2 mg) u zdravih ispitanika, približno se 73% radioaktivne doze eliminiralo mokraćom, a 15% stolicom, s time da se približno 2% doze radioaktivnog izotopa ugljika eliminiralo kao pomalidomid mokraćom, a 8% stolicom.
Following a single oral administration of radioactive ceritinib dose at 750 mg, ceritinib was the main circulating component in human plasma.
Nakon jednokratne peroralne primjene doze radioaktivnog ceritiniba od 750 mg, ceritinib je bio glavna cirkulirajuća komponenta u ljudskoj plazmi.
Following a single oral dose of 300 mg [14C] eluxadoline in healthy male subjects, 82.2% of the total [14C] eluxadoline was recovered in faeces in 336 hours and less than 1% was recovered in urine in 192 hours.
Nakon jednokratne peroralne doze od 300 mg [14C] eluksadolina u zdravih muških ispitanika, 82,2% ukupnog [14C] eluksadolina pronađeno je u stolici u roku od 336 sati i manje od 1% pronađeno je u urinu u roku od 192 sata.
Following a single oral dose of [14C]-labelled aripiprazole, approximately 27 % of the administered radioactivity was recovered in the urine and approximately 60 % in the faeces.
Nakon jedne oralne doze aripiprazola označenog izotopom[14C], približno 27 % primijenjene radioaktivnosti otkrilo se u mokraći, a približno 60 % u stolici.
Following a single oral dose of [14C]-labelled ruxolitinib in healthy adult subjects, elimination was predominately through metabolism, with 74% of radioactivity excreted in urine and 22% via faeces.
Nakon jednokratne oralne doze [14C]-označenog ruksolitiniba u zdravih odraslih ispitanika, eliminacija je uglavnom bila putem metabolizma, pri čemu je 74% radioaktivnosti bilo izlučeno u mokraću te 22% putem stolice.
Following a single oral dose of aprepitant 165 mg to healthy volunteers, the mean AUC0-∞ of aprepitant was 32.5 µghr/mL and the mean maximal aprepitant concentration was 1.67 µg/mL.
Nakon primjene jednokratne peroralne doze aprepitanta u dozi od 165 mg u zdravih dobrovoljaca, AUC0-∞ aprepitanta iznosio je 32,5 µghr/ml, a srednja vršna koncentracija aprepitanta iznosila je 1,67 µg/ml.
Following a single spot-on application of the product, indoxacarb and permethrin can still be detected in both skin and hair coat after 4 weeks post-treatment.
Nakon jedne spot-on primjene proizvoda, indoksakarb i permetrin može biti otkriven u koži i dlakama 4 tjedna nakon tretmana.
Following a single subcutaneous dose of ixekizumab in patients with psoriasis, mean peak concentrations were achieved within 4 to 7 days, across a dose range of 5 to 160 mg.
Nakon primjene jedne supkutane doze iksekizumaba u bolesnika s psorijazom, srednje vrijednosti vršnih koncentracija postignute su unutar 4 – 7 dana, u rasponu doza od 5 do 160 mg.
Following a single subcutaneous injection of 100 mg, the absorption of golimumab was similar in the upper arm, abdomen, and thigh, with a mean absolute bioavailability of 51%.
Nakon jednokratne supkutane injekcije u dozi od 100 mg golimumaba, apsorpcija golimumaba bila je slična na nadlaktici, abdomenu i bedru, a prosječna apsolutna bioraspoloživost iznosila je 51%.
Following a subcutaneous dose of Preotact, C-terminal fragments make up about 60-90 of the circulating forms of the molecule.
Nakon supkutanog doziranja Preotacta, fragmenti sa ugljikom na svojim krajevima čine 60-90% oblika molekule u cirkulaciji.
Following a washout period of at least 120 hours (5 days), the subjects received a single dose of 50 IU/kg of ALPROLIX.
Nakon razdoblja ispiranja lijeka iz organizma (engl. washout) od najmanje 120 sati (5 dana) ispitanici su primili jednu dozu od 50 IU/kg lijeka ALPROLIX.
Following a washout period of at least 96 hours (4 days), the subjects received a single dose of 50 IU/kg of ELOCTA.
Nakon razdoblja ispiranja lijeka iz organizma (engl. washout) od najmanje 96 sati (4 dana) ispitanici su primili jednu dozu od 50 IU/kg lijeka ELOCTA.
Following absorption from the skin, moxidectin is distributed systemically and is slowly eliminated from the plasma as manifested by detectable moxidectin concentrations in plasma throughout the treatment interval of one month.
Nakon resorpcije s kože, moksidektin se raspodijeli u organizmu i polako se odstranjuje kako je vidljivo iz mjerljivih koncentracija moksidektina u plazmi kroz interval primjene tijekom mjesec dana.
Following absorption from the skin, moxidectin is distributed systemically and is slowly eliminated from the plasma as manifested by detectable moxidectin concentrations in plasma throughout the treatment interval of one month.
Nakon resorpcije s kože, moksidektin se raspodijeli u organizmu i polako se odstranjuje kako je vidljivo iz mjerljivih koncentracija moksidektina u plazmi kroz vremenski interval primjene od mjesec dana.
Following absorption, citrate is converted into bicarbonate by the tissues.
Nakon apsorpcije, tkiva pretvaraju citrat u bikarbonat.
Following absorption, the ASA in Clopidogrel/Acetylsalicylic acid Zentiva is hydrolyzed to salicylic acid with peak plasma levels of salicylic acid occurring within 1 hour of dosing, such that plasma levels of ASA are essentially undetectable 1.5-3 hours after dosing.
Nakon apsorpcije, ASK iz lijeka Klopidogrel/acetisalicilatna kiselina Zentiva se hidrolizira u salicilatnu kiselinu čija se vršna koncentracija u plazmi pojavljuje unutar jednog sata od primjene, tako da je koncentraciju ASK u plazmi gotovo nemoguće odrediti poslije 1,5-3 sata nakon doziranja.
Following absorption, the ASA in DuoPlavin is hydrolyzed to salicylic acid with peak plasma levels of salicylic acid occurring within 1 hour of dosing, such that plasma levels of ASA are essentially undetectable 1.5-3 hours after dosing.
Nakon apsorpcije, ASK iz DuoPlavina se hidrolizira u salicilatnu kiselinu čija se vršna koncentracija u plazmi pojavljuje unutar jednog sata od primjene, tako da je koncentraciju ASK u plazmi gotovo nemoguće odrediti poslije 1,5-3 sata nakon doziranja.
Following absorption, the ASA in the combination of clopidogrel/acetylsalicylic acid is hydrolyzed to salicylic acid with peak plasma levels of salicylic acid occurring within 1 hour of dosing, such that plasma levels of ASA are essentially undetectable 1.5-3 hours after dosing.
Nakon apsorpcije, ASK iz kombinacije klopidogrel/acetilsalicilatna kiselina se hidrolizira u salicilatnu kiselinu čija se vršna koncentracija u plazmi pojavljuje unutar jednog sata od primjene, tako da je koncentraciju ASK u plazmi gotovo nemoguće odrediti poslije 1,53 sata nakon doziranja.
Following accidental ingestion, nausea, emesis, headache, myalgia and fever could occur after a single dose of 200 mg imiquimod which corresponds to the content of approximately 16 sachets.
Pri slučajnom gutanju jednokratne doze od 200 mg imikvimoda, što je otprilike sadržaj 16 vrećica, mogu se pojaviti slabost, glavobolja, mijalgija i vrućica.
Following accidental ingestion, nausea, emesis, headache, myalgia and fever could occur after a single dose of 200 mg imiquimod which corresponds to the content of more than 21 sachets of Zyclara.
Nakon slučajnog gutanja jedne doze od 200 mg imikvimoda što odgovara sadržaju od više od 21 vrećice Zyclare može doći do mučnine, povraćanja, glavobolje, mialgije i vrućice.
Following acute single overdoses ranging between 1,000 mg and 12,000 mg, seizures (generalized tonic-clonic seizures, status epilepticus) and cardiac conduction disorders were observed.
Opaženi su napadaji (generalizirani toničko-klonički napadaji, status epilepticus) te poremećaji srčanog provođenja nakon akutnih jednokratnih predoziranja dozama u rasponu između 1000 mg i 12 000 mg.
Following acute single overdoses ranging between 1,000 mg and 12,000 mg, seizures (generalized tonic-clonic seizures, status epilepticus) and cardiac conduction disorders were observed.
Opaženi su napadaji (generalizirani toničko-klonički napadaji, status epilepticus) te poremećaji srčanog provođenja nakon akutnih jednokratnih predoziranja dozama u rasponu između 1000 mg i 12000 mg.
following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel.
nakon adjuvantne kemoterapije doksorubicinom i ciklofosfamidom u kombinaciji s paklitakselom ili docetakselom.
Following administration of 14C-rivastigmine, renal elimination was rapid and essentially complete (>90 %) within 24 hours.
Nakon primjene rivastigmina označenog s 14C, eliminacija putem bubrega bila je brza i u osnovi potpuna (>90 %) unutar 24 sata.
Following administration of 14C-rivastigmine, renal elimination was rapid and essentially complete (>90%) within 24 hours.
Nakon primjene rivastigmina označenog s 14C, eliminacija putem bubrega bila je brza i u osnovi potpuna (>90%) unutar 24 sata.
Following administration of 2 mg daily, steady-state geometric mean Cmax, AUC(0-) and predose concentration were 22.2 ng/ml, 370 ng*hr/ml and 12.1 ng/ml, respectively with a low peak:trough ratio (1.8).
Nakon primjene doze od 2 mg na dan, u stanju dinamičke ravnoteže geometrijske srednje vrijednosti Cmax, AUC(0-) i koncentracije prije primjene doze iznosile su 22,2 ng/ml, 370 ng*hr/ml odnosno 12,1 ng/ml, uz nizak omjer vršne i najniže vrijednosti (1,8).
Following administration of 37 mg of lurasidone (equivalent to 40 mg lurasidone hydrochloride), the mean approximate apparent volume of distribution was 6000 L. Lurasidone is highly bound (~99%) to serum proteins.
Nakon primjene 37 mg lurasidona (što odgovara 40 mg lurasidonklorida), približna srednja vrijednost prividnog volumena distribucije bila je 6000 L. Lurasidon se u velikoj mjeri veže (~99%) na serumske proteine.
Following administration of 5 mg/kg infliximab every 8 weeks, the predicted median steady-state infliximab exposure (area under concentration-time curve at steady state, AUCss) in paediatric patients aged 6 years to 17 years was approximately 20% lower than the predicted median steady-state drug exposure in adults.
Nakon primjene lijeka infliksimab u dozi od 5 mg/kg svakih 8 tjedana, predviđena izloženost infliksimabu u stanju dinamičke ravnoteže (područje pod krivuljom koncentracija-vrijeme u stanju dinamičke ravnoteže, AUCss) u pedijatrijskih bolesnika u dobi od 6 do 17 godina bila je približno 20% niža nego predviđena izloženost u stanju dinamičke ravnoteže u odraslih.
Following administration of 5 mg/kg Remicade every 8 weeks, the predicted median steady-state infliximab exposure (area under concentration-time curve at steady state, AUCss) in paediatric patients aged 6 years to 17 years was approximately 20% lower than the predicted median steady-state drug exposure in adults.
Nakon primjene lijeka Remicade u dozi od 5 mg/kg svakih 8 tjedana, predviđena izloženost infliksimabu u stanju dinamičke ravnoteže (područje pod krivuljom koncentracija-vrijeme u stanju dinamičke ravnoteže, AUCss) u pedijatrijskih bolesnika u dobi od 6 do 17 godina bila je približno 20% niža nego predviđena izloženost u stanju dinamičke ravnoteže u odraslih.
Following administration of [111In]-radiolabelled Zevalin, whole body scans were performed at up to eight time-points, acquiring both anterior and posterior images.
Nakon primjene Zevalina radioaktivno označenog izotopom [111In] napravljene su snimke cijelog tijela u najviše osam vremenskih točaka, sprijeda i straga.
Following administration of [14C] temsirolimus, excretion was predominantly via the faeces (78%), with renal elimination of active substance and metabolites accounting for 4.6% of the administered dose.
Nakon primjene [14C] temsirolimusa, izlučivanje se pretežno odvijalo putem stolice (78%), dok se bubrezima eliminiralo 4,6% primijenjene doze u obliku djelatne tvari i metabolita.
Following administration of [14C]-emtricitabine, complete recovery of the emtricitabine dose was achieved in urine (~86%) and faeces (~14%).
Nakon primjene [14C]- emtricitabina, potpuna izolacija doze emtricitabina ostvarena je u urinu (~86%) i stolici (~14%).
Following administration of [14C]emtricitabine, complete recovery of the emtricitabine dose was achieved in urine (~ 86%) and faeces (~ 14%).
Nakon primjene [14C]emtricitabina, potpuna izolacija doze emtricitabina ostvarena je u urinu (~ 86%) i stolici (~ 14%).
Following administration of a crushed 5 mg apixaban tablet suspended in 60 mL of D5W and delivered via a nasogastric tube, exposure was similar to exposure seen in other clinical trials involving healthy subjects receiving a single oral 5 mg apixaban tablet dose.
Nakon primjene zdrobljene tablete apiksabana od 5 mg suspendirane u 60 ml 5%-tne otopine glukoze u vodi, te primijenjene putem nazogastrične sonde, izloženost je bila slična izloženosti uočenoj u drugim kliničkim ispitivanjima koja su uključivala zdrave ispitanike koji su primili jednu peroralnu dozu tablete apiksabana od 5 mg.
Following administration of a single 1000 mg dose in healthy subjects, an average of 19 % to 33 % of the administered dalbavancin dose was excreted in urine as dalbavancin and 8 % to 12 % as the metabolite hydroxy-dalbavancin.
Nakon primjene jednokratne doze od 1000 mg zdravim ispitanicima, prosječno je 19 % do 33 % primijenjene doze dalbavancina izlučeno u urinu u obliku dalbavancina, a 8 % do 12 % u obliku metabolita hidroksidalbavancina.
Following administration of a single 200 mg IV dose of Sivextro to 8 subjects with severe renal impairment defined as eGFR <30 mL/min, the Cmax was basically unchanged and AUC0-∞ was changed by less than 10% compared to 8 matched healthy subject controls.
Nakon primjene jednokratne intravenske doze lijeka Sivextro od 200 mg u 8 ispitanika s teškim oštećenjem funkcije bubrega definiranim kao eGFR <30 ml/min, Cmax je bio u načelu neizmijenjen, a AUC0-∞ je bio izmijenjen za manje od 10% u usporedbi s 8 odgovarajućih zdravih kontrolnih ispitanika.
Following administration of a single 200 mg oral dose of Sivextro, the pharmacokinetics of tedizolid are not altered in patients with moderate (n=8) or severe (n=8) hepatic impairment (Child-Pugh Class B and C).
Nakon primjene jednokratne peroralne doze lijeka Sivextro od 200 mg, farmakokinetika tedizolida nije se promijenila u bolesnika s umjerenim (n=8) ili teškim (n=8) oštećenjem funkcije jetre (Child-Pugh stadij B i C).